- Home
- CANF vs BBIO Comparison
CANF vs BBIO Comparison
Compare CANF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- BBIO
- Stock Information
- Founded
- CANF 1994
- BBIO 2015
- Country
- CANF Israel
- BBIO United States
- Employees
- CANF N/A
- BBIO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- BBIO Health Care
- Exchange
- CANF Nasdaq
- BBIO Nasdaq
- Market Cap
- CANF 7.9M
- BBIO 6.7B
- IPO Year
- CANF N/A
- BBIO 2019
- Fundamental
- Price
- CANF $1.11
- BBIO $34.17
- Analyst Decision
- CANF Strong Buy
- BBIO Strong Buy
- Analyst Count
- CANF 2
- BBIO 12
- Target Price
- CANF $14.00
- BBIO $57.09
- AVG Volume (30 Days)
- CANF 450.6K
- BBIO 3.1M
- Earning Date
- CANF 05-20-2025
- BBIO 04-29-2025
- Dividend Yield
- CANF N/A
- BBIO N/A
- EPS Growth
- CANF N/A
- BBIO N/A
- EPS
- CANF N/A
- BBIO N/A
- Revenue
- CANF $674,000.00
- BBIO $127,415,000.00
- Revenue This Year
- CANF $461.72
- BBIO $13.67
- Revenue Next Year
- CANF N/A
- BBIO $118.02
- P/E Ratio
- CANF N/A
- BBIO N/A
- Revenue Growth
- CANF N/A
- BBIO N/A
- 52 Week Low
- CANF $1.02
- BBIO $21.62
- 52 Week High
- CANF $4.69
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- CANF 40.05
- BBIO 44.19
- Support Level
- CANF $1.02
- BBIO $33.92
- Resistance Level
- CANF $1.20
- BBIO $39.16
- Average True Range (ATR)
- CANF 0.06
- BBIO 1.50
- MACD
- CANF 0.01
- BBIO -0.24
- Stochastic Oscillator
- CANF 40.91
- BBIO 10.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.